Western lowland gorilla ‘Nyati' dies at St. Paul's Como Zoo
Nyati was euthanized on Tuesday following what zoo officials say was 'a significant decline in her quality of life due to long-term neurological complications.'
The gorilla's medical issues started in 2020 with a diagnosis of Baylisascaris procyonis — a parasitic infection likely contracted at a young age. It was successfully treated but the parasite caused permanent brain lesions leading to gradual degeneration that affected her coordination, mobility, and motor skills.
For the last five years, veterinary and animal care staff at the zoo provided the gorilla with support such as medications, physical therapy, environmental modifications, and consultations with specialists.
'Nyati was deeply loved, not just by her care team, but by everyone who came to know her,' said Wes Sims, director of Animal Care and Health at Como Zoo, in a statement. 'Her life was shaped by medical challenges, but also by resilience, thoughtful care, and compassion. The decision to let her go was extremely difficult, but it was the most humane option for her.'
Nyati was a member of Como Zoo's family troop of western lowland gorillas. She was the daughter of Schroeder and Alice, and lived alongside her parents and fellow troop members.
Western lowland gorillas originate in central and western Africa and are critically endangered. In the wild, they face threats such as habitat loss, poaching, and disease outbreaks.
Como Park Zoo visitors witness birth of baby sloth
Cloud Cult, the Cactus Blossoms and Nur-D to headline the Minnesota Zoo's Wild Nights
Vulnerable animals find new homes after Roseville aquarium closure
Name a Bug fundraiser turns political — and profitable — for the Minnesota Zoo
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
a day ago
- Yahoo
North America Clinical Trials Market Forecast and Company Analysis Report 2025-2033 Featuring ICON, Wuxi AppTec, SGS, Syneos Health, PRA Health Sciences, Pfizer, IQVIA, and Medpace
The North America Clinical Trials Market is projected to grow from US$ 20.07 billion in 2024 to US$ 33.91 billion by 2033, registering a CAGR of 6.00% from 2025 to 2033. Key drivers include the increasing demand for novel treatments, rising prevalence of chronic conditions like COVID-19, diabetes, and various cancers, as well as supportive government R&D investments. The U.S. leads with robust infrastructure, top-notch research facilities, and significant technological advancements such as AI and decentralized trials. However, challenges persist with high operational costs and regulatory complexities. The market is vibrant, driven by rising clinical trial investments in sectors like oncology and enabled by innovative technologies, making it a promising field despite ongoing hurdles. North American Clinical Trials Market Dublin, July 29, 2025 (GLOBE NEWSWIRE) -- The "North America Clinical Trials Market Size and Forecast Report 2025-2033" report has been added to North America Clinical Trials Market is expected to reach US$ 33.91 billion by 2033 from US$ 20.07 billion in 2024, with a CAGR of 6.00% from 2025 to 2033. This is explained by longer clinical trial cycles, the demand for new treatments, and an increase in viral disorders as COVID-19 and diabetes, as well as advantageous government R&D spending. The growing need for novel medicines in a variety of therapeutic areas, including neurology, cardiology, and oncology, is the main factor propelling the North American clinical trials market's constant expansion. As a market leader, the United States enjoys the advantages of strong infrastructure, top-notch research facilities, and substantial investments in innovative healthcare. Drug development procedures are becoming faster and more efficient because to technological developments like big data, artificial intelligence, and decentralized clinical trials. Government financing and support for clinical research also contribute to the market's expansion. Nonetheless, the sector is still affected by issues including regulatory barriers, trouble recruiting patients, and expensive trial operating expenses. The market is nevertheless vibrant and is anticipated to continue evolving in spite of these market will expand quickly as a result of the growing number of clinical trials in North America, the pharmaceutical industry's expensive R&D costs, and the rising incidence of illnesses. Clinical trials for new or uncommon diseases are anticipated to benefit from the diverse disease profiles that are found to be growing with time due to the growing population in the North American region. Therefore, biopharmaceutical companies would be encouraged to increase their investment in clinical trials for a particular disease segment based on the number of patients with that of September 2022, there were over 13,323 ongoing clinical studies in various stages for cancer indications in the US, according to the US National Library of Medicine. Over the past few years, pharmaceutical corporations have likewise been spending more and more on research and development (R&D). This was mostly caused by a large number of patents expiring, which leaves many pharmaceutical companies with no choice except to create new medications. As a result, businesses are investing more in R&D to speed up the creation of medications through clinical trials, which will increase the market as a Drivers for the North America Clinical Trials Market Rising Prevalence of Chronic DiseasesOne of the main factors propelling the North American clinical trials market's expansion is the growing incidence of chronic illnesses including diabetes, cancer, and cardiovascular disorders. Clinical trials are being conducted by pharmaceutical corporations and research institutions due to the growing demand for new treatments and therapies as these diseases proliferate. These studies are essential for assessing the efficacy and security of possible treatments. Clinical trials are crucial for expanding medical knowledge and enhancing patient outcomes since chronic diseases frequently call for long-term management and innovative treatment choices. An older population, which is more likely to suffer chronic illnesses, supports this trend and increases the need for ongoing clinical research and innovative therapy in TechnologyTechnological developments are drastically changing the clinical trials environment in North America. Clinical study design, management, and execution are being improved by emerging technologies including artificial intelligence (AI), machine learning (ML), and big data analytics. These technologies aid in the real-time analysis of massive volumes of trial data, the more accurate identification of qualified applicants, and the prediction of patient outcomes. They thereby shorten trial durations, cut down on mistakes, and enhance decision-making. AI and ML are also being used to remotely monitor patient adherence and optimize protocol design, which lowers costs and increases trial efficiency. These developments make technology a potent growth engine in the dynamic clinical research environment since they not only speed up drug development but also increase trial success Investment in Oncology ResearchOne of the main factors propelling the growth of the clinical trials market is the rising incidence of cancer in North America, which has greatly increased funding for oncology research. The creation of novel cancer treatments is receiving a significant amount of support from public and private institutions as well as pharmaceutical firms. Clinical trials focusing on cancer, such as immunotherapies, targeted medicines, and personalized medical methods, have increased as a result of this financial boom. Research efforts have been sped up by the need to find efficient treatments and raise survival rates, which has prompted quicker trial initiation and increased cooperation between sponsors and research institutes. Since cancer is still one of the top causes of mortality, the region's clinical trial activity is growing in scope and size due to the strong emphasis on oncology in the North America Clinical Trials Market High Operational CostsOne major issue facing the clinical trials sector in North America is high operating costs. Significant costs are associated with conducting a clinical trial, such as hiring highly qualified personnel, investing in cutting-edge technology, building out the facility, adhering to regulations, and continuously gathering and tracking data. Complex trial designs, multi-site coordination, and longer study durations can all result in further increases in these expenses. Financial limitations can make it difficult for smaller biotech companies and research institutes to start or continue trials, frequently forcing them to rely on collaborations or outside funding. There is still a lot of pressure to strike a balance between cost effectiveness, data quality, and legal requirements. The cost of trials only goes up as they get more creative and customized, which is a major obstacle to larger research and development ComplexitiesOne of the biggest obstacles facing the clinical trials sector in North America is the complexity of regulations. To guarantee the safety and effectiveness of novel medications and therapies, organizations such as the U.S. Food and Drug Administration (FDA) implement strict and ever-changing regulations. Although these rules are necessary, following them can cause delays in trial approvals and raise compliance expenses dramatically. The procedure, which can be time- and resource-intensive, entails thorough documentation, ethical evaluations, and adherence to stringent criteria. Conducting multinational or multi-site studies also adds another level of complexity because different regulatory requirements in different locations need to be carefully maintained. These elements may cause delays in the start of trials, cause schedule disruptions, and increase the administrative load on sponsors and research institutions. Key Players Analyzed: Overviews, Key Persons, Recent Developments, Revenue ICON Plc Wuxi AppTec SGS SA Syneos Health PRA Health Sciences Inc Pfizer Inc. IQVIA Medpace Stryker Corporation Zimmer Biomet Holdings Orthofix Medical Inc. NuVasive Inc. Globus Medical Inc. Bejo Zaden BV Corteva Agriscience Key Attributes: Report Attribute Details No. of Pages 200 Forecast Period 2024 - 2033 Estimated Market Value (USD) in 2024 $20.07 Billion Forecasted Market Value (USD) by 2033 $33.91 Billion Compound Annual Growth Rate 6.0% Regions Covered North America Key Topics Covered: 1. Introduction2. Research & Methodology2.1 Data Source2.1.1 Primary Sources2.1.2 Secondary Sources2.2 Research Approach2.2.1 Top-Down Approach2.2.2 Bottom-Up Approach2.3 Forecast Projection Methodology3. Executive Summary4. Market Dynamics4.1 Growth Drivers4.2 Challenges5. North America Clinical Trials Market5.1 Historical Market Trends5.2 Market Forecast6. Market Share6.1 By Phases6.2 By Indications6.3 By Study Designs6.4 By Countries7. Phases7.1 Phase 17.2 Phase 27.3 Phase 37.4 Phase 48. Indications8.1 Autoimmune/Inflammation8.2 Pain management8.3 Oncology8.4 CNS Condition8.5 Diabetes8.6 Obesity8.7 Cardiovascular8.8 Others9. Study Designs9.1 Interventional9.2 Observational9.3 Expanded Access10. Countries10.1 United States10.2 Canada10.3 Mexico10.4 Rest of North America11. Porter's Five Forces Analysis11.1 Bargaining Power of Buyers11.2 Bargaining Power of Suppliers11.3 Degree of Rivalry11.4 Threat of New Entrants11.5 Threat of Substitutes12. SWOT Analysis12.1 Strength12.2 Weakness12.3 Opportunity12.4 Threat13. Key Players AnalysisFor more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment North American Clinical Trials Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Sign in to access your portfolio
Hamilton Spectator
2 days ago
- Hamilton Spectator
Impulse Dynamics® Completes Enrollment of Pivotal Trial for CCM-D® HF System and Earns Category 1 CPT Codes for CCM® Therapy
MARLTON, N.J., July 28, 2025 (GLOBE NEWSWIRE) — Impulse Dynamics®, a global medical device company committed to improving the lives of people with heart failure (HF), announced two major accomplishments, marking an inflection point in the advancement and accessibility of CCM® Therapy. 'We are proud to achieve these two pivotal milestones, which signal the growing acceptance of CCM® Therapy as a core component of HF treatment,' said Jason Spees, CEO of Impulse Dynamics®. 'The progress of the INTEGRA-D™ trial moves forward our path to seek regulatory approval of this first-of-its-kind, combined therapy for HF patients. Additionally, we appreciate the support of the ACC and HRS on our CPT coding initiative, and the AMA's timely review process that opens the door to broader access for patients and providers.' 'Many HF patients are treated with ICDs to protect against sudden death, but most do not treat HF itself. The INTEGRA-D™ trial is focused on evaluating a new device aimed at bridging this treatment gap by delivering symptom relief for HF patients receiving ICDs,' said Niraj Varma, M.D., Ph.D., Professor of Medicine and Director of Cardiac Pacing and Tachyarrhythmia at the Cleveland Clinic, and National Principal Investigator of the INTEGRA-D™ clinical trial. 'Completing enrollment for this trial is an important step towards evaluating this device for patients that could potentially benefit.' Each year, over 100,000 new ICDs are implanted in patients in the United States alone, adding to the estimated 800,000 individuals currently living with these devices (1,2). The CCM-D® HF System represents an important advancement, potentially offering these patients an option to life-saving technology and HF symptom relief. Additionally, the availability of CPT codes has expanded reimbursement pathways for the current Optimizer® device, helping increase access to this therapy for individuals living with heart failure, underscoring the maturation of CCM® therapy from an emerging innovation to a potentially established standard of care for HF patients. Together, these two milestones represent Impulse Dynamics®' unwavering focus on driving meaningful innovation for the millions of patients living with HF. About the INTEGRA-D™ Trial The INTEGRA-D™ trial is a multicenter, prospective, single-arm study evaluating the safety and efficacy of CCM-D® HF System. This April, the initial defibrillation efficacy (DE) cohort results were presented by Dr. Niraj Varma as a late-breaking clinical trial at the 2025 Heart Rhythm conference in San Diego, which marked the completion of the efficacy phase of the trial. The CCM-D® device successfully converted induced ventricular fibrillation (VF) in 100 percent of the enrolled patients in the DE cohort, meeting the primary efficacy endpoint. Once six months of follow-up is completed, the data will be submitted to the U.S. Food and Drug Administration (FDA) in a Premarket Approval (PMA) application. About the Optimizer® System and CCM® Therapy The Optimizer® system delivers CCM® therapy — the company's proprietary technology — to the heart, providing clinically meaningful improvement to quality of life for appropriate HF patients. CCM® therapy is designed to significantly improve heart contraction, allowing more oxygen-rich blood to be pushed out through the body[2]. CCM® therapy is indicated to improve six-minute hall walk, quality of life, and functional status of NYHA Class III HF patients who remain symptomatic despite guideline directed medical therapy, are not receiving CRT, and have a left ventricular ejection fraction ranging from 25 to 45 percent. CCM® is the brand name for cardiac contractility modulation — the non-excitatory electrical pulses delivered by the implantable Optimizer® device to improve heart contraction. CCM® therapy sends unique electrical pulses to the heart cells during the absolute refractory period. In doing so, CCM® helps the heart contract more forcibly. Impulse Dynamics® has completed numerous clinical studies, including several randomized controlled trials, the results of which appeared in more than 100 publications in leading medical journals. About Impulse Dynamics® Impulse Dynamics® is dedicated to advancing the treatment of HF for patients and the healthcare providers who care for them. The company pioneered its proprietary CCM® therapy, which uses the Optimizer® technology platform to improve quality of life in HF patients. CCM® therapy is delivered through the Optimizer® system, which includes an implantable pulse generator (IPG) implanted in a minimally invasive procedure and approved for commercial use in the United States and countries worldwide. More than 10,000 patients have received the therapy as part of clinical trials and real-world use, where it is shown to be safe and effective for HF patients with debilitating symptoms who otherwise have few effective options available to them. The company is currently engaged in another significant clinical trial called AIM HIGHer. The AIM HIGHer clinical trial is a multicenter study with the objective to evaluate the safety and efficacy of CCM® therapy in patients with symptomatic HF with an ejection fraction of 40 to 70 percent (inclusive). The trial is currently in its initial enrollment phase. To learn more, visit , or follow the company on LinkedIn, X (formerly Twitter), and Facebook. ### References:
UPI
5 days ago
- UPI
Wisconsin Lt. Gov. Sara Rodriguez launches gubernatorial bid
Wisconsin Lt. Gov. Sara Rodriguez is running for governor, the former emergency room nurse confirmed Friday. Photo courtesy of Governor of Wisconsin's office July 25 (UPI) -- Wisconsin Lt. Gov. Sara Rodriguez is running for governor, the former emergency room nurse confirmed Friday. "I'm used to being on my feet and getting right to the point, so let's go. First, I have an announcement. I'm running for governor," Rodriguez announced in a video released Friday, her 50th birthday. Rodriguez joins the Democratic primary field to replace Gov. Tony Evers, D-Wis. Evers, 73, announced in a video Thursday he would not seek re-election in November when he will turn 74. Evers has been the Governor of Wisconsin for six years and in public service for 50 years. Rodriguez is the first big name to enter the race to replace Evers. Milwaukee County Executive David Crowley confirmed Thursday to Spectrum News 1 Wisconsin that he plans to run. Former Wisconsin Lt. Gov. Mandela Barnes posted a photo of himself with Evers on X Thursday, thanking him for his service. Barnes served as lieutenant governor during Evers' first term and has hinted at a run for the office. Rodriguez previously worked in the emergency department of Baltimore's Mercy Medical Center. She later took a job at the U.S. Centers for Disease Control and Prevention between 2004 and 2006 before returning to Wisconsin. Increasing salaries for public teachers and expanding Medicaid access are among the promises Rodriguez makes in the video. "Look, we've got a real shot at flipping the state Legislature and with a Democratic governor, we can finally expand Medicaid and boost our healthcare workforce," Rodriguez says in the video, that also touches on her family's working-class roots in Wisconsin. "With a Democratic governor, we can finally expand Medicaid and boost our healthcare workforce, strengthen our farms, unions, and small businesses, fund our public schools and give teachers the raise they've earned. That's the right path."
